Davood KHoda Amorzideh on VTE and Bleeding in Cancer
Davood KHoda Amorzideh, Clinical Cardiologist at Farjam Heart Clinic, shared on LinkedIn:
”In the AVERT post-hoc analysis, cancer patients at intermediate-high VTE risk (Khorana_score ≥2) with elevated baseline GDF_15 had increased VTE risk, while elevated NT proBNP and CRP levels predicted bleeding.
Increasing hs-TnT levels from baseline to 1 month was associated with increased VTE risk.
Steven Hawken, Marc Carrier, Philip Wells, Dylan Burger, Tzu-Fei Wang’‘
Read the full article here.
Article: Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers Open Access
Authors: Danielle Carole Roy , Tzu-Fei Wang , Ranjeeta Mallick , Dylan Burger , Marc Carrier , Philip Wells , Steven Hawken
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH